Scotiabank analyst Louise Chen raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $558 from $495 and keeps an Outperform rating on the shares. The firm raised its price target on the stock given the firm’s increasing profitability of success for the pipeline, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals price target lowered to $541 from $546 at RBC Capital
- Vertex Pharmaceuticals price target raised to $577 from $572 at Bernstein
- Crispr Therapeutics price target raised to $74 from $62 at Evercore ISI
- Vertex Pharmaceuticals price target raised to $590 from $485 at Cantor Fitzgerald
- Balancing Solid CF Revenue With Kidney Pipeline Uncertainty: Why Stringer Maintains a Hold on Vertex